Ryvu Therapeutics S.A. (WSE:RVU)

Ryvu Therapeutics Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	151.76	160.07	57.94	101.92	83.24	136.22
Short-Term Investments	30.33	65.86	175.73	0.53	4.99	24.97
Cash & Short-Term Investments	182.09	225.93	233.67	102.45	88.23	161.19
Cash Growth	-25.86%	-3.31%	128.09%	16.11%	-45.26%	123.54%
Accounts Receivable	8.59	15.66	9.19	1.05	5.94	2.2
Other Receivables	12.95	10.92	23.65	258.85	5.8	5.75
Receivables	21.54	26.58	32.84	259.89	11.74	7.95
Inventory	1.21	1.21	2.12	1.76	1.96	1.68
Prepaid Expenses	-	-	-	2.35	1.63	0.58
Other Current Assets	19.33	18.72	9.77	1.48	0.69	0.98
Total Current Assets	224.16	272.44	278.39	367.93	104.25	172.36
Property, Plant & Equipment	70.94	72.74	77.56	82.22	91.18	91.16
Long-Term Investments	6.84	16.77	34.37	20.48	29.4	29.12
Other Intangible Assets	7.85	8.12	6.34	4.28	3.04	2.32
Long-Term Deferred Tax Assets	-	-	-	-	0.33	0.59
Other Long-Term Assets	8.72	8.72	6.55	0.08	0.6	0.09
Total Assets	318.51	378.78	403.2	474.98	228.81	295.64
Accounts Payable	23.75	31.15	23.14	12.58	11.69	6.26
Accrued Expenses	6.11	12.28	12.22	11.7	4.86	5.31
Short-Term Debt	0.05	0.29	0.13	0.06	0.02	0
Current Portion of Long-Term Debt	12.57	25.79	-	0.81	0.81	0.81
Current Portion of Leases	0.47	0.5	0.41	1.03	1.92	2.27
Current Income Taxes Payable	-	-	-	-	5.46	-
Current Unearned Revenue	27.67	35.71	31.53	16.71	8.95	14.56
Other Current Liabilities	-	2.21	2.27	1.93	2.5	4.6
Total Current Liabilities	70.61	107.93	69.7	44.81	36.2	33.81
Long-Term Debt	81.83	82.56	8.85	9.9	8.86	1.55
Long-Term Leases	1.3	1.39	0.37	0.87	1.58	2.77
Long-Term Unearned Revenue	44.87	42.74	64.26	75.8	20.26	27.5
Long-Term Deferred Tax Liabilities	0.01	-	-	-	0.44	6.04
Other Long-Term Liabilities	0	-	-	0.06	0.06	-
Total Liabilities	198.9	234.89	143.61	131.59	67.51	71.92
Common Stock	9.25	9.25	9.25	7.34	7.34	7.34
Additional Paid-In Capital	519.75	519.75	519.75	279.06	279.06	279.06
Retained Earnings	-136.72	-111.44	-0.01	92.1	175.88	261.54
Comprehensive Income & Other	-272.67	-273.67	-269.39	-35.12	-300.99	-324.22
Total Common Equity	119.6	143.88	259.59	343.39	161.3	223.72
Shareholders' Equity	119.6	143.88	259.59	343.39	161.3	223.72
Total Liabilities & Equity	318.51	378.78	403.2	474.98	228.81	295.64
Total Debt	96.21	110.53	9.76	12.67	13.19	7.41
Net Cash (Debt)	85.88	115.4	223.91	89.77	75.04	153.78
Net Cash Growth	-45.16%	-48.46%	149.42%	19.63%	-51.20%	144.52%
Net Cash Per Share	3.71	4.99	9.78	4.89	4.09	9.17
Filing Date Shares Outstanding	23.12	23.12	23.12	23.12	18.36	18.36
Total Common Shares Outstanding	23.12	23.12	23.12	23.12	18.36	18.36
Working Capital	153.56	164.51	208.69	323.12	68.05	138.55
Book Value Per Share	5.17	6.22	11.23	14.85	8.79	12.19
Tangible Book Value	111.76	135.77	253.26	339.11	158.26	221.4
Tangible Book Value Per Share	4.83	5.87	10.95	14.67	8.62	12.06
Land	-	7.47	7.47	7.47	7.47	7.47
Buildings	-	52.21	52.2	52.15	53	48.33
Machinery	-	16.09	15.38	14.15	13.8	13.11
Construction In Progress	-	0.35	-	-	0.61	4.58

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.